BioPharma Resources

Drug Trial Radar · NCT07364448

A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis

An Open-label, Single-arm Clinical Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

411

Actual

Start

Mar 12, 2026

Primary completion

Jun 22, 2026

Study completion Jun 22, 2026

Sponsor

Sponsor type
Industry
Collaborators
The First Hospital of Jilin University
First posted
Jan 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, single-arm study designed to collect safety data on hydronidone capsules in patients with chronic hepatitis B virus infection accompanied by liver fibrosis or fatty liver disease accompanied by liver fibrosis . Approximately 200 subjects will be enrolled, all of whom will receive hydronidone capsules three times daily, with three capsules per dose, resulting in a total daily treatment dose of 270 mg. The medication will be administered orally half an hour before meals for a total of 28 days.

Conditions

  • Chronic Hepatitis B With Hepatic Fibrosis

Interventions

  • Hydronidone capsulesDrug

    three times a day, 3 capsules each time,

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Any adverse events occurring in study participants following drug administration.Time frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jilin University First Hospital

    Jilin City, Changchun, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.